Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Evaluation of AVJ-301 (Absorb BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population

Next Previous
Trial Profile

A Clinical Evaluation of AVJ-301 (Absorb BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms ABSORB Japan
  • Sponsors Abbott Vascular

Most Recent Events

  • 26 Mar 2020 Results assessing long-term safety and effectiveness of Absorb BVS compared with XIENCE metallic DES in patients with de novo coronary artery lesions, published in the Circulation Journal.
  • 10 Jun 2019 Status changed from active, no longer recruiting to completed.
  • 25 Sep 2018 Results reporting influence of procedural technique on Everolimus-Eluting Stent outcomes within the ABSORB trials (ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top